Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHA:603882)
26.38
-0.12 (-0.45%)
Nov 20, 2026, 3:00 PM CST
SHA:603882 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 12,046 | 13,138 | 12,644 | 29,331 | 36,530 | 51,852 | |
Market Cap Growth | -13.15% | 3.91% | -56.89% | -19.71% | -29.55% | -11.92% |
Enterprise Value | 10,647 | 11,608 | 11,594 | 28,042 | 34,610 | 50,765 |
Last Close Price | 26.38 | 27.58 | 26.19 | 57.81 | 70.49 | 98.86 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 43.62 | - | - | 45.59 | 13.26 | 23.36 |
Forward PE | 30.67 | 26.51 | 20.32 | 31.68 | 18.29 | 27.15 |
PS Ratio | 2.04 | 2.18 | 1.76 | 3.44 | 2.36 | 4.34 |
PB Ratio | 1.86 | 1.92 | 1.69 | 3.43 | 4.12 | 7.95 |
P/TBV Ratio | 1.92 | 2.02 | 1.78 | 3.59 | 4.32 | 8.33 |
P/FCF Ratio | 18.39 | 16.88 | 27.49 | 56.84 | 32.99 | 45.66 |
P/OCF Ratio | 10.76 | 10.93 | 13.95 | 23.83 | 18.75 | 24.83 |
PEG Ratio | - | 1.28 | 1.35 | 6.93 | 4.57 | 6.79 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.81 | 1.93 | 1.61 | 3.28 | 2.24 | 4.25 |
EV/EBITDA Ratio | 14.77 | 72.71 | 43.87 | 32.36 | 9.41 | 16.61 |
EV/EBIT Ratio | 25.81 | - | - | 67.58 | 10.60 | 18.64 |
EV/FCF Ratio | 16.25 | 14.91 | 25.21 | 54.34 | 31.26 | 44.71 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.13 | 0.12 | 0.10 | 0.07 | 0.06 | 0.10 |
Debt / EBITDA Ratio | 1.18 | 3.38 | 2.01 | 0.59 | 0.15 | 0.20 |
Debt / FCF Ratio | 1.30 | 1.07 | 1.63 | 1.12 | 0.51 | 0.55 |
Net Debt / Equity Ratio | -0.23 | -0.29 | -0.22 | -0.22 | -0.27 | -0.31 |
Net Debt / EBITDA Ratio | -2.44 | -12.63 | -6.38 | -2.17 | -0.64 | -0.66 |
Net Debt / FCF Ratio | -2.36 | -2.59 | -3.66 | -3.64 | -2.13 | -1.79 |
Asset Turnover | 0.62 | 0.60 | 0.65 | 0.67 | 1.26 | 1.37 |
Inventory Turnover | 19.16 | 20.48 | 21.53 | 16.60 | 23.46 | 21.59 |
Quick Ratio | 2.99 | 3.09 | 3.11 | 2.95 | 2.22 | 2.02 |
Current Ratio | 3.16 | 3.24 | 3.28 | 3.07 | 2.33 | 2.13 |
Return on Equity (ROE) | 4.71% | -2.49% | -5.18% | 7.31% | 36.95% | 45.46% |
Return on Assets (ROA) | 2.94% | -1.73% | -3.44% | 5.01% | 22.36% | 25.53% |
Return on Invested Capital (ROIC) | 6.67% | -2.96% | -2.90% | 5.42% | 50.84% | 65.56% |
Return on Capital Employed (ROCE) | 5.60% | -2.10% | -2.20% | 4.60% | 35.10% | 38.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.29% | -1.32% | -3.02% | 2.19% | 7.54% | 4.28% |
FCF Yield | 5.44% | 5.93% | 3.64% | 1.76% | 3.03% | 2.19% |
Dividend Yield | 3.34% | 3.10% | 3.22% | 1.40% | 2.28% | 1.15% |
Payout Ratio | 148.44% | - | - | 130.46% | 22.13% | 7.66% |
Buyback Yield / Dilution | 0.29% | -0.71% | 0.28% | 0.15% | -0.13% | -1.00% |
Total Shareholder Return | 3.63% | 2.39% | 3.50% | 1.55% | 2.15% | 0.15% |